Right before the annual meeting, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has announced that Charles A. Sanders has announced retirement from company’s Board of Directors. As per the reports, he notified the company of the decision saying that he didn’t want to stand for re-election as a board member in the upcoming annual board meeting in May 2016.
Insights of Matter
In his statement, Sanders said that it’s the best time for him to consider retirement as the Board of BioCryst was well served by other experienced and skilled directors who could take the company to all new heights in the coming months. He was first appointed to BioCryst Board of Directors in year 2009, and has been an integral board member since then. He has contributed to company’s growth and market expansion to the best of his abilities and hopes that others would continue to help BioCryst forge ahead in the coming months.
Sanders talked about a number of subjects, issues and things, but sidelined comments on company’s policies, operations and practices.
Meanwhile, BioCryst announced that the recently conducted study of BCX4430 on mice with regard to Zika Virus cure would be presented at the prestigious WHO meeting in Switzerland. The primary objective of this test was to check the effect of company’s anti-viral BCX4430 on mice infected with Zika virus.
As part of this study, two dose levels (low and standard dose) were tested by scientists. In low-dose group of BCX4430, no mice survived the pre-determined 28-day period; however, in the standard dose group, 7-8 mice survived through 28-day period. The study was conducted at the well-known education institution – Utah State University under NIAID’s Animal Models of Infectious Disease Program.
The senior management team of the company is delighted to announce the initial progress and hopes that it will continue to execute successful trials in the coming months as well. More details about the upcoming tests will be shared at a later date.
